Nora Therapeutics to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

PALO ALTO, Calif., March 21, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the 21^st Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City on Friday, March 28, 2014 at 3:20 p.m. EDT.

About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit our website at www.noratherapeutics.com.

SOURCE Nora Therapeutics